SARS-CoV2: Clinical Trials

8 trials for SARS-CoV2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 unknown. 8 Phase 2, 4 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Unknown 8
Phase 34Unknown 4
Phase 11Unknown 1

Follow SARS-CoV2: new trials by email Literature Review of SARS-CoV2 trials Research Report on SARS-CoV2

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19
Ribavirin Capsules, Favipiravir - SARS-CoV2, COVID-19
Phase 2 / Phase 3UnknownThe Scientific and Technological Research Council of Turkey1002021-04-012021-04-02
Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients
Ivermectin Injectable Solution, Injectable Placebo, Zinc - Coronavirus Infection, COVID
Phase 1 / Phase 2UnknownSohaib Ashraf1802020-11-142021-02-17
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
Hydroxychloroquine Only Product in Oral Dose Form - Sars-CoV2, Coronavirus Infection
Phase 2 / Phase 3UnknownUniversity of Malaga19302020-09-012020-09-29
CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms
Cannabidiol, PLACEBO - SARS-CoV2
Phase 2 / Phase 3UnknownUniversity of Sao Paulo1002020-07-062021-09-28
Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19
SARS-CoV-2 convalescent plasma treatment, Standard care - Sars-CoV2, Covid-19
Phase 2 / Phase 3UnknownFundación Santa Fe de Bogota2362020-07-012020-06-11
Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)
Ciclesonide Inhalation Aerosol - Covid-19, Pneumonia, Viral
Phase 2UnknownOla Blennow, MD, PhD982020-05-292022-02-02
Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)
Mavrilimumab, Placebo - Covid-19, Acute Respiratory Failure
Phase 2UnknownOspedale San Raffaele502020-05-222020-05-26
NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE
IgIV - Sars-CoV2
Phase 2UnknownVersailles Hospital352020-05-052020-05-27

Narrower conditions

COVID-19 (6)  ·  Coronavirus Infections (2)  ·  Pneumonia, Viral (2)  ·  Respiratory Distress Syndrome (1)

Broader conditions

Coronaviridae Infections (6)  ·  Infections (6)  ·  Lung Diseases (6)  ·  Nidovirales Infections (6)  ·  Pneumonia (6)  ·  RNA Virus Infections (6)  ·  Respiratory Tract Diseases (6)  ·  Respiratory Tract Infections (6)  ·  Virus Diseases (6)  ·  Coronavirus Infections (4)  ·  Pneumonia, Viral (4)  ·  Respiration Disorders (1)

Interventions

COVID-19 Serotherapy (1)  ·  Cannabidiol (1)  ·  Dosage Forms (1)  ·  Ivermectin (1)  ·  Ribavirin (1)  ·  Saline Solution (1)  ·  Standard of Care (1)  ·  Zinc (1)  ·  ciclesonide (1)  ·  favipiravir (1)  ·  mavrilimumab (1)

Sponsors

Fundación Santa Fe de Bogota (1)  ·  Ola Blennow, MD, PhD (1)  ·  Ospedale San Raffaele (1)  ·  Sohaib Ashraf (1)  ·  The Scientific and Technological Research Council of Turkey (1)  ·  University of Malaga (1)  ·  University of Sao Paulo (1)  ·  Versailles Hospital (1)

Countries

Brazil (1)  ·  Colombia (1)  ·  France (1)  ·  Italy (1)  ·  Pakistan (1)  ·  Sweden (1)  ·  Turkey (Türkiye) (1)

Top investigators

Daniel P Andersson, MD, PhD (1)  ·  Juan C Morilla-Herrera, PhD (1)  ·  Lorenzo Dagna, MD (1)  ·  Moneeb Ashraf, MBBS (1)  ·  Muhammad Ashraf, PhD (1)  ·  Ola Blennow, MD, PhD (1)  ·  Shoaib Ashraf, PhD (1)  ·  Sohaib Ashraf, MBBS (1)

Results publications

PMID 34488858, PMID 34619044, PMID 36813503